Media stories about Ishares Nasdaq Biotechnology (NASDAQ:IBB) have trended positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ishares Nasdaq Biotechnology earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave headlines about the financial services provider an impact score of 45.9634656868907 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of NASDAQ:IBB traded down $0.76 during trading on Friday, hitting $105.96. 2,168,564 shares of the stock were exchanged, compared to its average volume of 2,633,675. Ishares Nasdaq Biotechnology has a 12-month low of $94.20 and a 12-month high of $119.30.
Ishares Nasdaq Biotechnology Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for Ishares Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ishares Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.